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ABSTRACT
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid
leukemia) shows distinctive biological and clinical features. Experimental evidence of the oncogenic potential of the nucleophosmin
mutant is, however, still lacking, and it is unclear whether other genetic lesion(s), e.g. FLT3 internal tandem duplication, cooperate with
NPM1 mutations in acute myeloid leukemia development. An analysis of age-specific incidence, together with mathematical modeling of
acute myeloid leukemia epidemiology, can help to uncover the number of genetic events needed to cause leukemia. We collected data
on age at diagnosis of acute myeloid leukemia patients from five European Centers in Germany, The Netherlands and Italy, and deter-
mined the age-specific incidence of AML with mutated NPM1 (a total of 1,444 cases) for each country. Linear regression of the curves
representing age-specific rates of diagnosis per year showed similar slopes of about 4 on a double logarithmic scale. We then adapted a
previously designed mathematical model of hematopoietic tumorigenesis to analyze the age incidence of acute myeloid leukemia with
mutated NPM1 and found that a one-mutation model can explain the incidence curve of this leukemia entity. This model fits with the
hypothesis that NPMc+ acute myeloid leukemia arises from an NPM1 mutation with haploinsufficiency of the wild-type NPM1 allele.
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Introduction
The nucleophosmin (NPM1) gene, which encodes a
nucleolar multifunctional protein, is frequently translo-
cated or mutated in hematologic malignancies.1,2
Mutation of NPM11 is one of the most common genet-
ic alterations in adult acute myeloid leukemia (AML),
occurring in about one-third of patients and accounting
for 50-60% of all AML cases with normal karyotype.3
Since NPM1 mutations were first discovered in AML in
2005,1 about 40 mutation variants have been identi-
fied.3 Despite molecular heterogeneity, all variants lead
to common changes at the C-terminus of the NPM1
protein4 which cause an increased nuclear export of the
nucleophosmin leukemic mutant and its aberrant accu-
mulation in the cytoplasm of leukemic cells;4-6 hence
the term NPMc+ (cytoplasmic-positive) AML.1,3 AML
with mutated NPM1 shows distinctive biological and
clinical features,3 including a unique gene expression
profile,7,8 a distinct microRNA signature,9 frequent
CD34-negativity (more than 95% of cases),1, 3 increased
incidence of FLT3-ITD mutations (about 40% of
cases),1 good response to induction therapy1 and a
favorable prognosis (in the absence of FLT3-ITD).10-15
These findings strongly suggest that AML with mutat-
ed NPM1 represents a new disease entity. Experimental
evidence of the oncogenic potential of the nucleophos-
min mutant is, however, still lacking, and it is unclear
whether other genetic lesion(s), such as FLT3-ITD,
cooperate with NPM1 mutations in generating the
leukemic phenotype. The multi-step theory of carcino-
genesis was conceived after mathematical modeling
demonstrated that the increasing cancer incidence with
age can be explained by several stochastic events need-
ed for tumorigenesis.16-19 A recently developed popula-
tion genetics model20 was used to study the age specif-
ic incidence of chronic myeloid leukemia and found
that the data are consistent with the hypothesis that
the BCR-ABL fusion oncogene alone is sufficient to
cause the chronic phase of the disease. Later on,
Vickers demonstrated that the age of onset of poly-
cythemia vera is in accordance with the assumption of
a single rate-limiting mutation and a small number of
stem cell divisions per year.21
To investigate the age-specific incidence of AML
with mutated NPM1, we adapted the one-mutation
model that was originally designed to describe chronic
myeloid leukemia age distribution.20 The model fits the
NPMc+ AML age-specific incidence curve assuming
plausible parameter values, supporting the hypothesis
that a single genetic event, the NPM1 mutation, is suf-
ficient to cause leukemia. The role of NPM1 mutations
in AML development is discussed in the light of these
findings.
Design and Methods
Patients
National registry-based AML incidence data with
details of NPM1 mutation status are not available.
Therefore, we collected data sets at five major European
Institutions involved in the diagnosis and treatment of
AML patients: (i) the Laboratory of Cytogenetic and
Molecular Diagnostics, University Hospital Ulm, repre-
senting the German-Austrian AML study Group
(AMLSG); (ii) the Laboratory of Hemopathology,
Institute of Hematology, University of Perugia, repre-
senting the Gruppo Italiano Malattie Ematologiche dell’
Adulto (GIMEMA); (iii) the Laboratory for Molecular
Diagnostics, University Hospital Carl Gustav Carus,
Dresden, Germany, representing the Deutsche
Studieninitiative Leukämie (DSIL); (iv) the Munich
Leukemia Laboratory (MLL), Munich, Germany; and (v)
the Department of Hematology, Erasmus University
Medical Center, Rotterdam, The Netherlands. 
A total of 1,444 AML patients (age range: 20-59; medi-
an 47) carrying a mutated NPM1 gene were included in
this study (n=476 from AMLSG; n=354 from GIMEMA;
n=251 from DSIL; n=223 from MLL; and n=140 from
The Netherlands). Exclusion criteria were: i) patients
under 20 years of age because few cases were available,
due to the low frequency of NPM1 mutations in this age
group22; and ii) patients over 59 years of age who are
often treated in local hospitals. Consequently, those
patients referred to major institutions for diagnosis and
treatment may not be representative of the population
of AML patients in this age group. 
Information on FLT3 status was available in
1,386/1,444 AML patients with mutated NPM1 (96%).
FLT3-ITD was detected in 553/1,386 cases (40%). For
analysis, the 1,444 NPM1-mutated AML patients were
stratified in 5-year age classes. 
For this study, we assume that the mutational event
needed to develop NPMc+ AML occurs independently
of local exposure to environmental leukemogenic fac-
tors and that the age specific rates of NPM1-mutated
AML patients 20-59 years in age reflect those of the gen-
eral population in the three European countries includ-
ed in the study. 
Modeling age specific incidence
The mathematical model by Michor et al.20 was adapt-
ed to analyze the AML incidence data. Our model is
based on the following considerations: (i) we consider a
population of N hematopoietic stem cells. Initially, all
cells are wild type and proliferate according to a sto-
chastic process known as the Moran model:23 every τ
days, a cell is chosen at random proportional to fitness
to divide; its offspring replaces another randomly cho-
sen cell. The population size is strictly constant; (ii) a
wild-type cell gives rise to a mutated cell at rate u per
cell division. A mutated cell has a relative growth rate
(fitness) of r. If r=1, the mutation is neutral as compared
to wild type cells; if r<1, the mutant is disadvantageous,
and if r>1, the mutant has a proliferation advantage over
the wild type cell. We assume that an NPM1 mutation
confers a fitness advantage to the cell, r>1; (iii) Our
model adheres to standard Moran process until a surviv-
ing mutant cell appears; thereafter, clonal growth is ini-
tiated that continues until the mutated cell population
reaches population size N
–
. Unlike the model designed
by Michor et al.,20 which assumes a constant population
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size of N cells, our model allows the mutant clone to
expand until a maximal size, N
–
. This change is intended
to account for the marked expansion of the initial cell
compartment which is peculiar to AML; (iv) the AML
detection rate is proportional to the number of mutated
cells present; if there are Nm mutated cells, the rate of
diagnosis is q Nm. From assumptions (i) and (ii) it follows
that the waiting time for the first successful (=surviving)
mutation has a negative exponential distribution, b=Nu
(1-1/r). Let a be the time since the occurrence of the first
surviving mutation. Then assumption (3) states that the
number of mutated cells, Nm, grows according to
N
•
m (a) = cNm (a)(1-Nm(a)/N
–
where c=(r-1)/τ and Nm (0)=1/(1-1/r). To account for
the significant expansion of the mutated clone, we
assume N
–
>>N. Finally, if (q) is the proportionality con-
stant between the rate of detection and the number of
mutated cells (assumption iv), then the probability of
diagnosis20 at time t is given by
(1)
We compared the predictions of equation (1) with the
direct computer simulation of the stochastic process.
The simulation is performed by first determining the
time at which the first surviving mutated cell arises in a
population of N wild type cells; this time follows a neg-
ative exponential distribution with mean 1/b. Once
such a cell has emerged, the branching process of clonal
expansion is simulated by choosing a cell for reproduc-
tion or for death at random at each time step. The prob-
ability that the number of wild type cells, N, increases
by one is given by
(2a)
where . Here d denotes the
death rate of both wild type and mutated cells. The
probability that the number of mutated cells, Nm,
increases by one is given by
(2b)
The probabilities that the numbers of wild type and
mutated cells decrease by one are respectively given by
(2c)
(2d)
A patient is diagnosed at rate qNm and is entered into
the incidence data base of his age class. Online
Supplementary Figure 1 shows the fit of equation (1) and
system (2). Under particular circumstances, i.e. when
the waiting time for the first successful mutation is long
and clonal expansion occurs fast and reaches large cell
numbers, the incidence data can be a kinked curve. A
more detailed mathematical investigation of such situa-
tions is forthcoming (Michor F. et al., in preparation) but
will not be discussed here since the experimentally
determined incidence data is a straight line on a doubly
logarithmic plot. 
Finally, we compared equation (1) with the experi-
mental data, which allowed us to quantify AML-specif-
ic parameters.
Statistical analysis
The χ2 test (α<0.05) was used to assess independence
of the age distribution of cases by center of diagnosis.
The likelihood ratio test, comparing a Poisson regression
model including age, country, and age x country interac-
tion terms with the nested model without the interac-
tion term was performed to evaluate dependence of age
specific NPM1-mutated AML rates on the country.
Results
Age specific rates of acute myeloid leukemia with
mutated NPM1 are similar in different countries 
First, we determined whether age specific incidence
curves of AML with NPM1 mutations were comparable
in Italy, Germany and The Netherlands. The AML cases
registered by each center do not provide a precise esti-
mate of incidence, since the population that is referred
to each study center for diagnosis cannot be identified.
However, it is important to note that the slope of the
incidence curve is needed for our purpose, not popula-
tion-based incidence figures. Therefore, population data
from the U.S. Census Bureau website (http://www.cen-
sus.gov/ipc/www/idb, accessed on February 12, 2008)
were used to obtain demographic data (person-years)
for each country. In each country the number of AML
cases was stratified into age classes. The cases in each
age class were divided by the total population in that
age class, which provided the age specific rate of diag-
noses per year per million inhabitants. 
Chi-square testing of the age distribution of cases on
center of diagnosis was not significant (p=0.48) indicat-
ing that, although absolute incidence levels vary
because they reflect the percentage of the general popu-
lation that is covered by participating centers, number
of cases by age class does not differ among study cen-
ters (Table 1). The likelihood ratio test comparing the
Poisson model which includes a country x age class
interaction with the simpler model without the interac-
tion term (Online Supplementary Table 1) was non-signif-
icant (p=0.85). Together, these findings provide evi-
dence that AML data from the three countries are com-
parable. In particular, AML incidence curves analyzed
via linear regression all showed a slope of about 4 on a
log-log scale (Figure 1). 
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The one-mutation model fits the incidence curve 
of acute myeloid leukemia with mutated NPM1
We next adapted the one-mutation mathematical
model that was originally designed to describe chronic
myeloid leukemia epidemiology20 to investigate age
specific incidence data in AML with NPM1 mutations.
The model provided adequate data fitting and generat-
ed slopes similar to real age specific incidence curves
from patients (Figure 2) from Germany, The
Netherlands, and Italy. The corresponding χ2 and p val-
ues for the three countries were 0.02027 (p=0.9899),
0.00862 (p=0.9956), and 0.15275 (p=0.9264). The fitting
procedure provided estimates of the parameters in each
country (Table 2) generating numbers that are biologi-
cally plausible (see below). 
The initial hematopoietic stem cell (HSC) compart-
ment was quantified as 1.03×104-1.14×104. This fits
with experimental findings24 suggesting that, although
humans require more blood cells per lifetime than mice
(because of their larger size and longer life expectancy),
the total number of human HSCs is equivalent to the
total number of HSCs in mice, which has been shown
to be of about 11,400±5,400.24
The maximum number of mutated cells generated by
the model was about N
–
=1013. This number is consistent
with the high tumor burden observed in leukemia
patients, if one assumes that, under physiological condi-
tions, the amount of human nucleated marrow cells per
kg body weight has been calculated to be approximately
2.1×1010 (1.5×1012 in a subject of 70 kg).25 The relative fit-
ness of mutated cells spanned the range 1.38-1.61. The
mean cell generation time (i.e. the time needed for a cell
to divide), was between 2.67 and three days, which con-
curs with early experimental findings26 and with clinical
data.3 In the NPM1-mutated AML case, the rate of cancer
detection per mutated cell was found to be in the range
of 7.77×10-5-1.58×10-4 days. This implies that the total
rate of detection (qN) is in the range of 0.26-1.78, which
is higher than previous estimates in chronic myeloid
leukemia.20 Leukemic clones are initiated by single NPM1
mutations occurring at rates ranging from 2.43×10-9 to
4.86×10-9 days per cell division. Taken together, these esti-
mates imply that for a single individual the waiting time
for the appearance of a surviving mutation is on average
1/(Nu(1-1/r)), which is about 5532, 9940 and 8779 days
for Germany, The Netherlands and Italy respectively. 
Table 1. Cumulative incidence of the NPM1-mutated acute myeloid
leukemia in Germany (DE), the Netherlands (NL) and Italy (IT).* 
Age class Cum P (DE) Cum P (NL) Cum P (IT)
20-24 8.87×10-7 9.73×10-7 5.92×10-7
25-29 2.55×10-6 2.07×10-6 3.58×10-6
30-34 4.34×10-6 4.36×10-6 6.29×10-6
35-39 8.17×10-6 7.72×10-6 1.10×10-5
40-44 1.35×10-5 1.29×10-5 1.76×10-5
45-49 1.93×10-5 1.84×10-5 2.56×10-5
50-54 3.05×10-5 2.45×10-5 3.72×10-5
55-59 3.81×10-5 3.49×10-5 4.85×10-5
*Corresponding curves have a slope of about 4 on a doubly logarithmic scale
(slope DE=4.038, slope NL=4.043, slope IT=4.332) as seen in Figure 1.
Figure 1. Incidence data for the NPMc+ acute myeloid leukemia in
Germany (DE), The Netherlands (NL) and Italy (IT). Linear regres-
sion shows a slope of about 4 on a doubly logarithmic scale.
Figure 2. The incidence data can be fit to the one-mutation model
assuming plausible parameter values for Germany (A), The
Netherlands (B) and Italy (C). χ2 and corresponding p-values report-
ed as labels in the corresponding figures show the quality of the fit.
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FLT3 gene status does not influence the age specific
incidence of acute myeloid leukemia with mutated
NPM1
Internal tandem duplication (ITD) at the FLT3 gene
locus has been implicated as a cooperating genetic alter-
ation in various AML subtypes.27,28 Since FLT3-ITD fre-
quently associates with NPM1 mutations1 and appears
to abrogate the favorable prognostic effect of NPM1
mutations in AML1,15,29 we determined whether the age
incidence of NPM1-mutated AMLs with FLT3-ITD dif-
fers from cases with wild-type FLT3. No significant dif-
ference emerged in the slopes of FLT3-ITD-positive and
-negative AML with mutated NPM1 (Figure 3). The
quality of fit with the model-generated data was ade-
quate and similar to the quality of fit for all AMLs with
NPM1 mutations (Figure 4). The one-mutation model
parameters for fitting FLT3-ITD positive and FLT3-ITD
negative AML with mutated NPM1 are reported in
Table 3. The slopes of the three groups (NPM1 mutated,
NPM1 mutated/FLT3-ITD, NPM1-mutated/FLT3 wild-
type) are not significantly different according to the
Mann-Witney U test (p>0.05) (Online Supplementary
Table 2).
Discussion
In this study, we adapted a one-mutation mathemati-
cal model that was originally designed to describe
chronic myeloid leukemia epidemiology20 to investigate
the age specific incidence data in AML with mutated
NPM1. The model fits the NPMc+ AML age specific
incidence curve for plausible parameter choices, sup-
porting the hypothesis that a single genetic event, the
NPM1 mutation, is sufficient to cause this type of
leukemia. However, evidence derived from in vitro func-
tional studies and experimental models are required to
confirm or refute this hypothesis. 
Our findings add to the body of evidence that the
NPM1 mutation is a founder genetic lesion in NPMc+
AML: i) cytoplasmic mutated nucleophosmin is specific
for AML1, 30, 31 and clinically shows close association with
AML of de novo origin1,32-34; ii) all NPM1 mutations gen-
erate changes at the C-terminus of nucleophosmin pro-
tein which appear to maximise nuclear export of NPM
leukemic mutants,3,35-37 pointing to cytoplasmic disloca-
tion of the mutants as the central event for leukemoge-
nesis; iii) NPM1 mutations are mutually exclusive with
other recurrent genetic abnormalities,1,38 with the excep-
tion of rare cases in which both NPM1 and CEPBA (or
FLT3-ITD) mutations are found;15 iv) they are stable dur-
ing the course of the disease39,40 as the same type of
NPM1 mutation is consistently detected at relapse in
medullary and extramedullary sites;40 and v) quantita-
tive real-time PCR shows that NPM1 mutations disap-
pear at complete remission.41,42
The major finding in the present study is that the one-
mutation mathematical model can explain the age spe-
cific incidence in NPMc+ AML. This hypothesis is in
contrast to current concepts in AML development
which, like other human cancers, is believed to be a
consequence of more than one oncogenic hit.43 Indeed,
several animal models of AML clearly point to leukemo-
genesis as a multi-step process.43 Moreover, in vitro find-
ings that the NPM1 leukemic mutant specifically coop-
erates with the E1A adenovirus to transform primary
MEFs in soft agar44 suggest that NPM1 mutations need
to act in close concert with other oncogenic hits. In MEF
cells, this mutual cooperation involves the NPM1
Figure 3. Incidence data for the NPMc+ acute myeloid leukemia
bearing FLT3-ITD (A) or FLT3 wild-type for Germany (DE), The
Netherlands (NL) and Italy (IT) (B).
Table 2. Parameters of the one-mutation model for all NPM1
mutated acute myeloid leukemias.
Parameter Definition Germany The Netherlands Italy
r Relative fitness 1.42 1. 38 1.61
τ Mean cell generation time 2.79 2.67 3.00
q Rate of cancer 1.58×10-4 1.56×10-4 7.77×10-5
detection per 
mutated cell
N Standard number 1.10×104 1.14×104 1.03×104
of hematopoietic 
stem cells
u Mutation probability 4.86×10-9 2.43×10-9 4.19×10-9
per cell division
N
–
Maximum number 1.00×1013 1.00×1013 1.00×1013
of mutated cells
Values were obtained via minimization of the least squares function in eq. (2). 
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mutant inhibiting the E1A-elicited p19(Arf) induction
and E1A overcoming NPM1 mutant-induced cellular
senescence.44 Furthermore, an activating mutation of the
FLT3 gene (FLT3-ITD) leading to an internal tandem
duplication of the juxtamembrane portion of FLT3, a
receptor which plays an important role in controlling
proliferation and/or survival of hematopoietic progeni-
tors, has been implicated as a cooperating genetic alter-
ation in various AML subtypes.27,28 Since FLT3-ITD has
been detected in about 40% of AML with mutated
NPM1,1 it has been suggested that it may play an impor-
tant role also in this leukemia subtype. 
The findings of this paper suggest that the role of
FLT3-ITD as a cooperative mutation in the pathogenesis
of NPMc+ AML should be interpreted with caution. In
fact, no difference can be detected between the slopes
of the age specific incidence of FLT3-ITD-positive and -
negative NPMc+ AML, supporting the view that NPMc+
AML is a homogeneous group irrespective of the FLT3
mutational status. This is consistent with the observa-
tion that the unique gene expression profile of AML
with mutated NPM1, i.e. upregulation of HOX genes
and downregulation of CD34,7,8 does not appear to be
significantly influenced by the FLT3 gene status. This is
also in keeping with the clinical observation that FLT3-
ITD can appear or disappear in NPM1-mutated AML
patients during the course of the disease.39 Moreover, in
oncogenic cooperation tests, the NPM1 leukemic
mutant and FLT3-ITD did not cooperate to transform
mouse embryonic fibroblasts (MEFs).44 Hypothetically,
FLT3-ITD may not be necessary for the development of
AML but rather provide a selective advantage for
leukemic cells that already harbor the NPM1 mutation.
Unfortunately, there is as yet no experimental mouse
model to prove or disprove this hypothesis. However,
this interpretation would at least fit with the clinical
observation that FLT3-ITD appears to abrogate the
favorable prognostic impact of NPM1 mutations,29 sug-
gesting that it may play a role at later stages of NPMc+
AML, leading to a more aggressive AML phenotype. 
Thus, how can we reconcile the results of our one-
mutation mathematical model with current evidence
that favor the hypothesis that AML is the result of more
than one oncogenic hit43 ? One possible explanation is
that NPMc+ AML arises from the concerted action of an
NPM1 mutation and another leukemogenic event
A. Liso et al. 
Figure 4. Fitting the incidence data with the one-mutation model
(A) leads to plausible parameter values in all cases (NPMc+ acute
myeloid leukemia with FLT3-ITD or FLT3 wild-type) for all three
countries (Germany, The Netherlands (B) and Italy (C)). χ2 and cor-
responding p-values reported as labels in the corresponding figures
show the quality of the fit. 
Table 3. Parameters of the one-mutation model for the NPM1-
mutated/FLT3-ITD and NPM1-mutated/FLT3 wild-type (wt) subsets.
Parameter definition Germany The Netherlands Italy
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N Standard number 1.00 1.11 1.09 1.11 1.10 1.10
of hematopoietic 
stem cells 
(×104)
N
_
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of mutated cells 
(×1012)
r Relative fitness 1.57 1.40 1.34 1.54 1.85 1.62
τ Mean cell 3.41 2.79 2.87 2.90 2.86 2.90
generation 
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q Rate of cancer 1.29 1.84 2.54 0.64 0.32 0.43
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cell division 
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occurring at the same time. Since the NPM1 mutant has
intrinsic oncogenic properties44 and in knock-out mice
NPM haploinsufficiency results in a MDS-like syn-
drome45 and in overt leukemia,46 an attractive hypothe-
sis would be that these alterations act together to cause
NPMc+ AML.3,47 Indeed, NPM1 mutations are associated
with haploinsufficiency of wild-type NPM in leukemic
cells, since mutations are always monoallelic3 and lead
to dislocation of functionally active wild-type NPM
from the nucleoli to the cytoplasm through formation of
heterodimers with the NPM1 leukemic mutant.4
However, other scenarios cannot be excluded with
certainty only on the basis of the mathematical model.
NPM1 and yet undiscovered mutation(s) may act syner-
gistically such that their actions cannot be discerned
when investigating incidence data. Moreover, even
though NPM1 mutations may be sufficient to cause
leukemia, secondary mutations (e.g. FLT3-ITD) could
increase the fitness of leukemic cells and/or result in the
development of more aggressive AML stages. Finally, it
is still possible that cancer incidence data cannot be
used to identify the number of genetic changes neces-
sary to cause cancer. Therefore, further experimental
studies are warranted to clarify the oncogenic role of
NPM1 mutations and other putative cooperating genet-
ic lesions in NPMc+ AML. 
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